Chinese company Synovik Biotech Limited has announced that its vaccine against corona virus has been shown to be safe during human trials and has been successful in improving the immune response.
The announcement suggests that the vaccine may be a defense against the cod 19 disease caused by the novel coronavirus.
According to a statement issued by the Beijing-based company, the human trial did not show any serious side effects from the vaccine, dubbed Corona Week, and the people who were given the vaccine tested positive for the virus two weeks later. There was a strong immune response, including antibodies needed to neutralize the virus.
The company released preliminary results of the first and second phases of the vaccine on humans, which included 743 healthy people between the ages of 18 and 59.
143 people were included in the first phase while 600 people were included in the second phase.
These individuals were given a dose of the vaccine or a placebo (a harmless substance given as medicine) in 2 schedules.
The people who were vaccinated had more than 90% levels of antibodies to the virus after 14 days, but no serious side effects were seen.
According to a company spokesperson, the results of the vaccine on another group will be released soon. The trial period was 28 days and these results will be published in educational journals.
It was then requested to start the third and final phase.
The vaccine uses a type of corona virus and is one of five experimental vaccines in China that have entered the final stages of human testing, after which general use will be approved.
The company also announced a partnership with Brazil’s Instituto Butantan this month to work on a third phase of trials in Brazil, where cases of the corona virus are on the rise.
Lockdowns and social distance measures in many countries have helped reduce the rate of the disease, but experts believe that the epidemic can be prevented only when an effective vaccine is developed against it.
Authorities in Brazil have also approved a partnership with China to test the final phase of a vaccine being developed by Oxford University in the United Kingdom.
Commenting on the findings, Weidong Yin, president of the Chinese company, said: “The first and second rounds of research have shown that Corona Week is safe and can trigger an immune response against the virus.”
“Completing the first and second phases with these encouraging results is another important milestone we have achieved in the fight against Code 19,” he added.
“We are also investing in building a production unit to develop the vaccine so that more doses can be prepared and people can be protected from code 19. Like our other vaccines, we have a global reach,” he said. But Corona is committed to preparing for the week, it is our mission to provide vaccines to eradicate this human disease.
Senevik began developing the vaccine in January 2020 in collaboration with leading Chinese research institutes.
The company was allowed to start the first and second phase trials on April 13 by the Chinese company NMPA.
A recent report suggests that China could potentially become the first country in the world to introduce vaccines against coronavirus in September for people at risk, even during clinical trials. But why not continue the work.
According to a report in the British daily Telegraph, Chinese medical authorities have drafted guidelines on vaccines to introduce treatment for corona virus in the United States.
More than any other country, China has entered the second phase of human testing with the highest number of 5 vaccines.
Success in vaccine development will help revive China’s corona-infected economy, while US President Donald Trump’s rapid vaccine plans will be hit.
According to William Lee, an economist at the Malikan Institute, a think tank that specializes in vaccine development, “If China comes up with a vaccine that is widely accepted around the world, it will have a huge impact.”
Chinese Premier Li Keqiang told a global vaccine conference in early June that China had so far spent 4 billion yuan on vaccines and treatments for code 19 and would spend more than double that.
The outbreak has prompted the Chinese government to step up projects in key areas of national security, including robotics and biomedicine, while setting up dozens of laboratories to study more germs.
“We need to build confidence in technology in specific areas, we need to rely on our own strengths rather than others, so that from one billion, The overpopulation can be protected.
A Chinese military medical institute and private biotech company Ken Sino have partnered to develop the vaccine, led by Chen Wei.
A live virus is being used for this vaccine that will carry genetic material into human cells, which will help eradicate the virus, in fact it is a conventional vaccine.
Will trigger a more powerful immune response than before.
Scientists have been working on this technology for decades, especially with regard to HIV, but humans have not yet approved it.
The administration will soon need volunteers for the fastest trials in China, as the country now has a limited number of COD 19 patients and may have to work in other countries to test the effectiveness of vaccines.
Viruses change themselves to survive, and experts say the vaccines currently being worked on are at risk of becoming ineffective or unusable after preparation.
He added that the longer the duration of the epidemic, the greater the likelihood of types of the virus, but whether these types will be more dangerous to humans or less will depend on genetic mutations.
But experts say progress is accelerating, according to Nicholas Thomas, a professor at the University of Hong Kong. “Most people forget the fact that the virus has been with us for barely seven months.”
“Globally, whatever is happening politically, but at the technical level, there is an amazing level of partnership and data sharing,” he said.
In April, Chinese medical officials expressed hope that the vaccine, which protects against code 19, would be available for emergency use by September and for the general public early next year.
Gao Fu, head of China’s Center for Disease Control and Prevention, told China Global Television Network that clinical trials of the vaccine were currently in its second or third phase in the country and that they could be on track until the second wave of the epidemic. May be available.
Gao Fu said: “We are at the forefront of vaccine development and it is likely that a vaccine for emergency use will be ready by September. These new vaccines could be used for certain groups of people, such as medical workers.” ۔
“The vaccine is likely to be available to the general public early next year, but it will depend on progress in its preparation,” he said.